Diode laser treatment of posterior retinopathy of prematurity

Ruth Axer-Siegel, Moshe Snir, Dan Cotlear, Ayala Maayan, Ronit Frilling, Irit Rosenbaltt, Dov Weinberger, Israel Kremer, Lea Sirota

Abstract

Aims—To study the efficacy of infrared diode laser for the treatment of posterior retinopathy of prematurity (ROP).

Methods—48 eyes of 25 premature babies (mean birth weight 779 (SD 127.7) g; mean gestational age 25.5 (SD 1.47) weeks) with threshold ROP in zone I and posterior zone II were treated by the indirect infrared (910 nm) diode laser. Confluent burns were applied to the avascular retina. In 18 eyes, an additional row of laser burns was added posterior to the ridge.

Results—Favourable anatomical results were noted in 41 eyes (85.4%). ROP stage 5 developed in two eyes, ROP stage 4A developed in four eyes, and ROP stage 4B in one eye. Three of the eyes with stage 4A eyes were successfully buckled; the fourth was not operated on and remained demarcated by laser scars. No complications were noted.

Conclusion—In this series, the diode laser was found to be a safe and effective treatment for posterior ROP.

The 1990 publication of the Cryotherapy for Retinopathy of Prematurity Cooperative Group (CRYO-ROP) showed that cryoablation of the avascular retina in zone I retinopathy of prematurity (ROP) reduces the very high unfavourable anatomical outcome (92%), but only to 75%. These poor results have been partly attributed to the technical difficulties of reaching the border of the posteriorly located ridge, and the large area of avascular retina that has to be destroyed. In a further report, the same group noted that babies with regressed ROP following successful cryotherapy may have atrophic changes in the macula which result in decreased visual acuity despite a favourable anatomical outcome. Some of these degenerative changes are caused by the uncontrollable extension of the treatment scars in the avascular retina, which is located anterior to the ridge near the macula in zone I ROP.

Data accumulated over recent years have indicated that laser treatment may be superior to cryotherapy for threshold ROP. Eyes treated with the binocular indirect ophthalmoscopic diode laser were found to be less myopic than cryo treated eyes, and the functional outcomes were better. Both treatment modalities had a similar effect on the structure of the retina, except in infants with posteriorly located ROP, in whom cryotherapy was successful in only 20–40% of cases compared with 80–88% for diode laser therapy.

The aim of the present study was to report on our experience with the infrared diode laser for the treatment of threshold ROP in zone I or posterior zone II.

Subjects and methods

All consecutive premature infants with threshold ROP hospitalised in our centre, as well as premature neonates referred from other hospitals, between December 1996 and December 1999 were treated with the diode indirect laser (Iris Medical Instruments, Inc, Mountainview, CA, USA). Threshold ROP was classified according to the CRYO-ROP Study Group as 5 or more contiguous or 8 cumulative clock hours of stage 3 ROP in zone I or II in the presence of “plus” disease. The anterior border of posterior zone II was defined for the purpose of our study as 1 disc diameter peripheral to the outer border of zone I (Fig 1). This definition was formulated prospectively and used rigidly throughout the study. The zone of disease was determined according to the most posteriorly located neovascularisation. The location of the retinopathy was documented as zone I when a sector of at least 1 clock hour of neovascularisation was present within zone I. The number of sectors within the posterior zone was not assessed. The identification of the zone and the staging were performed by two independent ophthalmologists. In cases of disagreement, a third observer was consulted and the majority ruled.
Table 1 Patients with unfavourable anatomic outcome

<table>
<thead>
<tr>
<th>Patient no</th>
<th>Zone</th>
<th>Stage</th>
<th>Laser to vascular retina</th>
<th>Operation</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>II</td>
<td>II</td>
<td>5</td>
<td>4A</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>I</td>
<td>I</td>
<td>4A</td>
<td>No</td>
<td>laser barrage</td>
</tr>
<tr>
<td>3</td>
<td>I</td>
<td>I</td>
<td>—</td>
<td>4A</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>I</td>
<td>I</td>
<td>5</td>
<td>4B</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>II</td>
<td>II</td>
<td>—</td>
<td>4A</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Results

During the period between December 1996 and December 1999, 33 consecutive neonates underwent photocoagulation with the diode laser for threshold ROP. Of these, eight were excluded from the study, seven with ROP in the anterior zone II and one neonate with zone I disease who died of sepsis 3 weeks after laser treatment. The remaining 25 included seven patients referred from other hospitals and 18 from our medical centre. There were 16 males and nine females. Birth weight was less than 915 g in all but one patient with hydrops, and ranged from 540–1130 g, with a median of 732.5 g and an average of 779 (SD 127.7) g. Gestational age ranged from 23–27 weeks, with an average of 25.5 (1.47) weeks. Mean gestational age at diagnosis of ROP was 33.2 (1.08) weeks and at laser treatment, 36 (1.93) weeks. Both eyes were treated in 23 patients and one eye in two, for a total of 48 eyes, including 23 with zone I ROP and 25 with posterior zone II ROP. The preretinal neovascularisation extended from 5 to 12 hours circumferentially, with a mean of 7.75 (2.4) hours. Plus disease was noted in all eyes.

The laser variables were as follows: power level 0.3 to 0.5 W, exposure time 0.2–0.5 seconds, and number of applications 800–1550, with an average of 1243 (SD 283). Retreatment was performed in 11 eyes (23%); however, the retreatment rate decreased from 29% during the first 2 years of performance of the procedure to 12% in the third year.

In 18 eyes, we added one to two rows of photocoagulation spots posterior to the ridge, avoiding the blood vessels and the area closer than 1 disc area to the fovea. Ten of the 18 eyes underwent the supplementary posterior laser treatment 2–3 weeks after the first treatment.

Three patients had intraoperative bradycardia and pulmonary distress; two were successfully intubated and ventilated during treatment. In the third patient, the session was stopped after treatment of one eye was completed and resumed for the second eye 2 days later. The only intraoperative ocular complication was a small local preretal bleeding in two patients. The follow up period ranged from 3–25 months with a mean of 14 months.

An unfavourable anatomic outcome was observed in seven eyes (14.6%) of five patients. The data are shown in Table 1. Four eyes of four babies had 4A detachment; three were successfully buckled, and one was not operated...
Diode laser for posterior ROP

Discussion

Posterior ROP carries a high risk of unfavourable anatomical outcome. According to several reports, the natural history of zone I ROP is associated with a poor anatomical outcome in 92% of eyes.\textsuperscript{1,13–15} In the CRYO-ROP study,\textsuperscript{1} treatment of zone I disease with cryotherapy had a 75% chance of an unfavourable result, compared to 22% for zone II disease, as the results for anterior and posterior zone II ROP have not been examined separately, the chance of an unfavourable outcome for posterior zone II disease would be expected to range between 22% and 75%. Although many researchers believe that the clinical course of posterior zone II disease is similar to that of zone I,\textsuperscript{11} the behaviour of threshold ROP in posterior zone II disease is not known.

Eighteen of the 26 neonates (69%) in our study had posterior zone ROP. In the series of Noonan and Clark,\textsuperscript{9} 30/64 cryo treated eyes (47%) had posterior ROP and only 14/59 (24%) laser treated eyes. This difference may have been due to differences in postnatal care or differences in the definition of the posterior zone. We defined the anterior border of the posterior zone II as 1 disc diameter peripheral to the outer border of zone I, even when this area extended for 1 clock hour. The identification of the zone was performed during the clinical examination. By contrast, Noonan and Clark\textsuperscript{9} classified theirs retrospectively, based on a review of the medical records; eyes were diagnosed as having anterior zone ROP if there was doubt as to whether the ROP was posterior or mid-zone II. This method may have led to an underestimation of the number of cases of posterior zone ROP. In the recent series of Banach \textit{et al.},\textsuperscript{16} zone I ROP was reported in 4/56 (7.1%) patients in cohort 1 and 18/51 (35.3%) in cohort 2. A possible explanation for this disparity was that some of the patients in cohort 2 were treated in a different hospital, with differences in oxygen administration, surfactant treatment, and related factors. In our series, zone I disease occurred in 23 eyes of 12 babies, nine of whom were hospitalised in our centre. The rate of nine babies out of 26 (34.6%) (19 posterior zone and seven anterior zone II) corresponds roughly to that of cohort 2 in the series of Banach \textit{et al.}.\textsuperscript{16}

These data indicate that the zone of threshold ROP varies in different studies. These differences may play a part in the natural history as well as in the anatomical and functional results of laser treatment.

Recent reports have shown that laser treatment for ROP is at least as effective as cryotherapy, and for zone I disease probably even superior.\textsuperscript{3–11,16–20} Capone \textit{et al.}\textsuperscript{20} noted a favourable outcome in 83.3% of 30 eyes with zone I threshold ROP that were treated with diode laser, and Fleming \textit{et al.}\textsuperscript{11} reported successful results with diode laser photoocoagulation for prethreshold posterior ROP. In the latter study, 10 eyes had zone I disease and eight had posterior zone II disease, which was defined as ROP located in the posterior half of zone II. All eyes showed complete regression of the retinopathy after treatment; however, the authors' criterion for treatment was the presence of plus disease, and none of the eyes had neovascularisation at the time of laser application. Noonan and Clark\textsuperscript{3} reported an 87.5% success rate in a series of 14 eyes with posterior ROP treated with diode or argon laser. These results compare favourably with the authors' 40% success rate with cryotherapy in 30 eyes with posterior zone ROP. The authors attributed the good results in this combination of the change in treatment modality and the treatment of prethreshold disease in some cases. They stated that they now treat zone I disease as soon as plus disease develops. Vander \textit{et al.}\textsuperscript{21} reported on a series of 36 eyes of 19 patients with posterior ROP. Seventeen babies were treated with the diode laser and two with the argon laser. The posterior zone was defined as the field seen with a Volk 25 dioptre indirect condensing lens. The edge of the optic disc was placed at the edge of the field of view, and the extent of the vascularisation at the opposing edge of the lens was defined as being within the posterior zone. This posterior zone is roughly comparable with zone I, though judging from their illustration it may have been slightly larger. The eyes were randomised for treatment at prethreshold or threshold disease. An unfavourable anatomical structural outcome was noted in 16% of the 19 early treatment eyes and in 18% of the 17 eyes treated at threshold. All these series showed better results than those of the CRYO-ROP study for posteriorly located disease.\textsuperscript{1}

ROP occurs in two phases. The first phase is characterised by vaso-oblitration which causes hypoxia of the non-perfused avascular retina. In the second phase, retinal neovascularisation occurs. According to Pierce \textit{et al.},\textsuperscript{22} vascular endothelial growth factor (VEGF) is produced just anterior to the developing blood vessels. Using a rat model of ROP, Dorey \textit{et al.}\textsuperscript{23} found that VEGF expression occurs. According to Pierce \textit{et al.},\textsuperscript{22} vascular endothelial growth factor (VEGF) is produced just anterior to the developing blood vessels. Using a rat model of ROP, Dorey \textit{et al.}\textsuperscript{23} showed that the inner nuclear layer of oxygen exposed retinas exhibited messenger RNA of VEGF expression in the peripheral avascular area, which sharply diminished in the vascular retina. Neovascularisation occurred adjacent to the regions of greatest expression. In a cat model of ROP, Stone \textit{et al.}\textsuperscript{24} found that VEGF expression was maximal where vessels were about to form. They suggested that therapeutic ablation of the ischaemic avascular retina suppresses the abnor-
nal angiogenesis which is stimulated by VEGF and other growth factors. Moreover, it probably promotes chorioretinal adhesions that may contribute to the favourable anatomical outcome. This was supported by the study of Banach et al demonstrating that dense confluent diode laser treatment of the avascular retina significantly reduces the progression of threshold ROP compared with a less dense laser pattern. However, a significant proportion of eyes still progress to retinal detachment.

Treatment of the retina posterior to the ridge was reported already in 1978 by Hindle and Leyton. These authors performed cryotherapy on the ridge and the adjacent areas anterior and posterior to it, using one or two rows of cryophotocoagulations. They reported regression of the mesenchymal ridge and no scattering in most of the treated eyes. In 1995, O'Keefe et al performed diode laser photocoagulation posterior to the ridge in eight eyes of five infants—six eyes with stage 4A ROP and two eyes (in one premature baby) with advancing stage 3+ ROP. Total regression was noted in six eyes of four patients and a flat macula with peripheral retinal detachment in two eyes of two patients. The authors suggested that diode laser photocoagulation of the vascular retina posterior to the ridge may be useful in progressive stage 3 and stage 4A ROP after failed treatment of the avascular retina. The laser was recommended for the area posterior to the ridge because it creates a chorioretinal adhesion by its relatively deep burn.

We treated the vascular retina posterior to the ridge by application of one to two rows of laser burns either during the primary procedure or 2–3 weeks later, during supplementary treatment. The ridge itself was not treated. In the cases that received supplementary treatment, the axial growth of the eye caused anterior displacement of the laser scars away from the macula, thereby enabling additional laser treatment at least 1 disc diameter temporal to the fovea. When regression occurred, the laser scars grew and became almost confluent. The fibrovascular ridge remained as an atrophic white extraretinal tissue, surrounded by laser scars. One eye with 4A detachment had an area of 2 clock-hours of temporal retinal detachment, demarcated by two rows of laser scars posteriorly.

Our 85.4% rate of favourable anatomical results is similar to the rates reported in previous series of posterior threshold ROP treated with the diode laser. Furthermore, in four of the seven eyes with an unfavourable outcome, the macula remained attached throughout the entire follow up period. However, caution must be exercised when comparing our series with others, owing to the difference in the methodology and in the definition of the posterior zone. Since some cases of stage 4 disease are self-limiting, the possible role of the laser scars as a barrier against traction retinal detachment should probably be studied in a randomised trial.

In conclusion, diode laser treatment of posterior ROP yielded a favourable anatomical outcome in 41/48 eyes (85.4%). Four additional eyes had attached macula after buckling procedure. The role of laser treatment posterior to the ridge remains controversial, and randomised clinical trials are needed to test its efficacy.